LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    Joint Statement: The Data Act is a leap into the unknown

    01/02/2023
    POSITION PAPER

    1 February 2023

    Data sharing will be fundamental to the success of the European economy in the coming years, with data contributing at least €1 trillion by 2030. But the Data Act as it stands is a huge leap into the unknown, affecting the fundamentals of European companies’ data-driven business models, with only the promise of a better data future.

    As the policymaking process accelerates on this pivotal proposal, industry warns against possible unintended economic consequences across data value chains.

    At a time of great economic upheaval, record-high energy prices and the negative impact of pandemic and war on global supply chains, what industry needs to succeed is stability, not more uncertainty. Before opening Pandora’s box, the Data Act’s rules need to be tried and tested in real-world market conditions to make sure that they work for European businesses.

    The opposite result will be achieved if the Data Act rushes to impose widespread data sharing onto unsuspecting businesses already overwhelmed by an unprecedented amount of new regulation.

    The European Parliament and Council should take sufficient time to preserve European innovation and competitiveness. Concretely, they must ensure that the proposal:

    • Protects trade secrets, safety, security and privacy by including effective safeguards to prevent data misuse and unfair competition;
    • Gives certainty to companies as to if and what they must share, starting by setting clear definitions, e.g. ‘data’ and ‘data holder’;
    • Enables companies to find mutually beneficial data-driven relationships by recognising the central role of flexible contractual terms, including on compensation;
    • Differentiates between the business-to-business (B2B) and the business-to-consumer (B2C) contexts and provides different rules and safeguards accordingly;
    • Sets strict conditions to business-to-government (B2G) data requests and limits the scope to public emergencies, to avoid endless litigation and uncertainty for Member States;
    • Promotes cloud adoption through an applicable and adaptable switching framework that reflects technical reality and market needs, and provides legal clarity;
    • Does not create new obstacles to international data flows, which are critical to European companies’ operation and growth in foreign markets;
    • Allows for a longer transition period, of at least 36 months, to give companies time to prepare, and does not apply retroactively to ensure predictability of current investments.

    We trust that EU policymakers will take the time to build a framework that supports Europe’s data economy.

    Joint statement: The Data Act is a leap into the unknown


    Download
    2020_12_G_PP_Comitology Joint StatementDownload

    Share
    Communications Team
    Communications Team

    Related posts

    06/03/2026

    Bene Meat Technologies joins EuropaBio: Advancing Cultivated Meat in Europe


    Read more
    06/02/2026

    OECD: A comparison of the innovation and regulatory environments for biotechnology and biosolutions across the European Union and the United States


    Read more
    03/02/2026

    Ecolab Life Sciences joins EuropaBio: Helping Shape the Future of Life Sciences Manufacturing in Europe


    Read more

    Important links

    • Bene Meat Technologies joins EuropaBio: Advancing Cultivated Meat in Europe
    • The Association of Biopharmaceutical Manufacturers in Latvia (BRAL) joins EuropaBio: Promoting Access to Innovative Therapies

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.